Apogenix develops protein therapeutics that could transform the treatment of life-threatening diseases by targeting critical pathways involved in the growth, migration, and apoptosis of diseased cells.
The company's lead drug candidate APG101 is currently being evaluated in patients with glioblastoma (GB) - a disease with a tremendous need for new and effective therapies. A randomized controlled phase II study in recurrent GB has shown that APG101 prolongs overall survival and improves quality of life, while exhibiting an excellent safety profile. Apogenix is also developing a companion diagnostic to identify patients who may respond best to treatment with APG101.
APG101's unique mode of action supports its significant potential for the treatment of other malignant diseases, such as myelodysplastic syndromes (MDS) as well as solid tumors beyond GB.
© 2013 BioRN Cluster Management GmbH • All Rights Reserved • Contact & Legal Notice